Quantitative Analysis of Serum IgG Galactosylation Assists Differential Diagnosis of Ovarian Cancer
Quantitative Analysis of Serum IgG Galactosylation Assists Differential Diagnosis of Ovarian Cancer
复制标题
血清 IgG 半乳糖基化的定量分析有助于卵巢癌的鉴别诊断。
DOI：
10.1021/pr4003992
复制
发表时间：
2013-09-01
影响因子：
4.4
通讯作者：
Gu, Jianxin
中科院分区：
文献类型：
--
作者：
Qian, Yifan;Wang, Yisheng;Gu, Jianxin
CA-125是卵巢癌检测中最常用的生物标志物，但由于其特异性较差，无法提供准确的诊断，因为它在许多良性妇科疾病中也可能增加。因此，迫切需要减少假阳性结果。与健康对照相比，在各种恶性肿瘤中发现血清 IgG 末端半乳糖基化 N-聚糖减少。在这里，这种 IgG 半乳糖基化的改变被扩展到卵巢癌和 CA-125 水平相似升高的良性疾病之间的研究，试图有效地区分假阳性受试者和卵巢癌患者。在对 58 名 CA-125 水平升高 (>35 U/mL) 的患者进行的研究中，根据公式 G0/(G1 + G2.2)，通过 IgG 双半乳糖基 (G2)、单半乳糖基 (G1) 和半乳糖基化 (G0) N-聚糖的相对强度来测量 IgG 半乳糖基化程度。恶性组的这一比率显着高于良性组（0.74 vs 0.34；p < 0.0001）。 ROC 分析表明，特异性从 65.2%（仅通过 CA-125 测试）提高到 84.6%，同时通过在当前检测中结合 IgG 半乳糖基化的定量分析，将灵敏度保持在 90%。结果表明，将 IgG 半乳糖基化的定量改变与 CA-125 相结合可能会产生一种整体更稳健的卵巢癌鉴别诊断方法。
CA-125, the most frequently used biomarker for ovarian cancer detection, cannot provide accurate diagnosis due to its poor specificity as it may also increase in many benign gynecological conditions. Thus, reducing the false-positive outcomes is urgently needed. Decrease in terminal galactosylated N-glycans of serum IgG has-been found in various malignancies compared to healthy controls. Here, this alteration of IgG galactosylation was extended to be investigated between ovarian cancer and benign conditions with similar elevated CA-125 levels, in an attempt to effectively distinguish between false-positive subjects and ovarian cancer patients. In the study of 58 patients with elevated CA-125 levels (>35 U/mL), the degree of IgG galactosylation was measured from the relative intensities of IgG digalactosyl (G2), monogalactosyl (G1), and agalactosylated (G0) N-glycans according to the formula G0/(G1 + G2.2). This ratio was found significantly higher in the malignant group than in the benign group (0.74 vs 0.34; p < 0.0001). ROC analysis demonstrated an improved specificity from 65.2% (by CA-125 test alone) to 84.6%, while maintaining sensitivity at 90% by incorporating quantitative analysis of IgG galactosylation in the current assay. The results suggest that combining quantitative alteration of IgG galactosylation with CA-125 may generate an overall more-robust approach for differential diagnosis of Ovarian cancer.